Incyte Corporation
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803
Phone: (855) 446-2983Website: https://www.incyte.com/Careers: www.incyte.com/join-us/join-incyte.aspxPatient Assistance Program: www.incytecares.com
Latest news
- FDA Approves Zynyz (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
22 March 2023 - Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma
20 December 2022 - Incyte Announces FDA Approval of Pemazyre (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
26 August 2022 - Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream for the Treatment of Vitiligo
18 July 2022 - Incyte Announces FDA Approval of Jakafi (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
22 September 2021 - FDA Approves Opzelura (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD)
21 September 2021 - Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
23 July 2021 - Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
11 June 2021 - Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
17 May 2021 - Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis
19 February 2021
Drugs Associated with Incyte Corporation
Incyte Corporation manufactures, markets and/or distributes more than 4 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Jakafi
Generic name: ruxolitinib Drug class: multikinase inhibitors |
31 reviews | 7.4 / 10 |
|
Opzelura
Generic name: ruxolitinib Drug class: topical antineoplastics |
2 reviews | 9.5 / 10 |
|
Pemazyre
Generic name: pemigatinib Drug class: multikinase inhibitors |
1 review | 1.0 / 10 |
|
Zynyz
Generic name: retifanlimab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
